IFN-γ- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers

被引:126
作者
Bin Zhang [1 ,2 ,3 ]
Karrison, Theodore [4 ]
Rowley, Donald A. [2 ,3 ]
Schreiber, Hans [2 ,3 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio Canc Inst, San Antonio, TX 78229 USA
[2] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[3] Univ Chicago, Committee Immunol, Chicago, IL 60637 USA
[4] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA
关键词
D O I
10.1172/JCI33522
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Tumors elicit antitumor immune responses, but over time they evolve and can escape immune control through various mechanisms, including the loss of the antigen to which the response is directed. The escape of antigen-loss variants (ALVs) is a major obstacle to T cell-based immunotherapy for cancer. However, cancers can be cured if both the number of CTLs and the expression of antigen are high enough to allow targeting of not only tumor cells, but also the tumor stroma. Here, we showed that IFN-gamma and TNF produced by CTLs were crucial for the elimination of established mouse tumors, including ALVs. In addition, both BM-and non-BM-derived stromal cells were required to express TNF receptors and IFN-gamma receptors for the elimination of ALVs. Although IFN-gamma and TNF were not required by CTLs for perforin-mediated killing of antigen-expressing tumor cells, the strong inference is that tumor antigen-specific CTLs must secrete IFN-gamma and TNF for destruction of tumor stroma. Therefore, bystander killing of ALVs may result from IFN-gamma and TNF acting on tumor stroma.
引用
收藏
页码:1398 / 1404
页数:7
相关论文
共 61 条
[1]   Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes [J].
Bai, XF ;
Liu, JQ ;
Li, O ;
Zheng, P ;
Liu, Y .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (10) :1487-1496
[2]   Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy [J].
Bai, Xue-Feng ;
Liu, Jin-Qing ;
Joshi, Pramod S. ;
Wang, Lizhong ;
Yin, Lijie ;
Labanowska, Jadwiga ;
Heerema, Nyla ;
Zheng, Pan ;
Liu, Yang .
CANCER RESEARCH, 2006, 66 (16) :8241-8249
[3]   Human tumor antigens recognized by T lymphocytes [J].
Boon, T ;
vanderBruggen, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :725-729
[4]   Immunopotentiating role of IFN-γ in early and late stages of type 1 CD8 effector cell-mediated tumor rejection [J].
Dobrzanski, MJ ;
Reome, JB ;
Dutton, RW .
CLINICAL IMMUNOLOGY, 2001, 98 (01) :70-84
[5]  
DOUKAS J, 1990, J IMMUNOL, V145, P1727
[6]   Induction of CD4+ and CD8+ T-cell responses to the human stroma antigen, fibroblast activation protein:: Implication for cancer immunotherapy [J].
Fassnacht, M ;
Lee, J ;
Milazzo, C ;
Boczkowski, D ;
Su, Z ;
Nair, S ;
Gilboa, E .
CLINICAL CANCER RESEARCH, 2005, 11 (15) :5566-5571
[7]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400
[8]   INHIBITION OF ENDOTHELIAL-CELL PROLIFERATION BY GAMMA-INTERFERON [J].
FRIESEL, R ;
KOMORIYA, A ;
MACIAG, T .
JOURNAL OF CELL BIOLOGY, 1987, 104 (03) :689-696
[9]   PURIFICATION, CHARACTERIZATION, AND ANTITUMOR-ACTIVITY OF NONRECOMBINANT MOUSE-TUMOR NECROSIS FACTOR [J].
HARANAKA, K ;
CARSWELL, EA ;
WILLIAMSON, BD ;
PRENDERGAST, JS ;
SATOMI, N ;
OLD, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (11) :3949-3953
[10]   THE ANTITUMOR FUNCTION OF TUMOR NECROSIS FACTOR (TNF) .1. THERAPEUTIC ACTION OF TNF AGAINST AN ESTABLISHED MURINE SARCOMA IS INDIRECT, IMMUNOLOGICALLY DEPENDENT, AND LIMITED BY SEVERE TOXICITY [J].
HAVELL, EA ;
FIERS, W ;
NORTH, RJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (03) :1067-1085